Table 3 Multivariate analysis for post-SCT overall survival in untransformed MDS (n = 199).

Age at SCT (per 10 years)

0.97

0.82–1.16

0.8

Therapy-related MDS

0.76

0.46–1.24

0.3

IPSS-R Very High risk

1.72

1.06–2.79

0.027

 Wild type

Ref

–

–

 Mutated monoallelic

3.72

1.77–7.78

<0.001

 Mutated biallelic

4.39

2.58–7.45

<0.001

 HMA

Ref

–

–

 Untreated

1.68

0.39–7.22

0.5

 Intensive chemotherapy

0.00*

0.00– > 9.99*

>0.9*

 Venetoclax-based

0.58

0.26–1.26

0.2

HCT-CI

1.14

1.03–1.27

0.014

 2011–2016

Ref

–

–

 2017–2023

0.76

0.40–1.45

0.4

 No

Ref

–

–

 Yes

0.91

0.50–1.67

0.8